14 completed, 4 recruiting, 2 terminated, 1 active not recruiting. 12 Phase 3, 6 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 7, Recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 2 | 6 | Completed 5, Recruiting 1 |
| Phase 1 | 5 | Completed 4, Terminated 1 |
Follow Razoxane: new trials by email Literature Review of Razoxane trials Research Report on Razoxane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma Biospecimen Collection, Bone Scan, Computed Tomography - Pleuropulmonary Blastoma | Phase 3 | Recruiting | Children's Oncology Group | 110 | 2025-03-21 | 2026-08-25 |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Acute Myeloid Leukemia | Phase 3 | Recruiting | Children's Oncology Group | 1400 | 2020-07-21 | 2026-09-17 |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin - Ganglioneuroblastoma, High Risk Neuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 42 | 2019-03-04 | 2026-06-02 |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 3 | Recruiting | Children's Oncology Group | 750 | 2018-05-14 | 2026-08-25 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride - Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Children's Oncology Group | 46 | 2013-04-29 | 2024-01-05 |
| Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Cyclophosphamide, Dexrazoxane, Doxorubicin Hydrochloride - Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone | Phase 3 | Completed | Children's Oncology Group | 642 | 2010-11-24 | 2026-01-23 |
| Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride - PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma | Phase 3 | Completed | National Cancer Institute (NCI) | 236 | 2009-09-15 | 2026-06-30 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride - Sarcoma | Phase 1 | Completed | Children's Oncology Group | 24 | 2008-08-01 | 2014-07-04 |
| Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone - Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 134 | 2005-02-01 | 2017-12-12 |
| Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT filgrastim, cisplatin, cyclophosphamide - Central Nervous System Tumor, Pediatric | Phase 2 | Completed | Dana-Farber Cancer Institute | 25 | 2003-02-01 | 2015-12-24 |
| Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride - Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2002-11-01 | 2013-01-17 |
| A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracyclines Dexrazoxane - Extravasation | Phase 2 / Phase 3 | Completed | Valerio Therapeutics | 57 | 2002-04-01 | 2015-10-21 |
| Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide - Cardiac Toxicity, Inflammatory Breast Cancer | Phase 3 | Terminated | National Cancer Institute (NCI) | 396 | 2001-05-01 | 2013-01-16 |
| Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride - Cardiac Toxicity, Sarcoma | Phase 3 | Completed | Children's Oncology Group | 253 | 1999-09-01 | 2014-08-05 |
| Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease bleomycin sulfate, filgrastim, cyclophosphamide - Cardiac Toxicity, Lymphoma | Phase 3 | Completed | Children's Oncology Group | 219 | 1997-03-01 | 2014-07-24 |
| Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease bleomycin sulfate, filgrastim, dexrazoxane hydrochloride - Cardiac Toxicity, Lymphoma | Phase 3 | Completed | Children's Oncology Group | 294 | 1996-10-01 | 2013-08-26 |
Showing 20 of 21. Sign in to see all of them.
Cardiotoxicity (6) · Lymphoma (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Sarcoma (3) · Blast Crisis (2) · Burkitt Lymphoma (2) · Ganglioneuroblastoma (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Large-Cell, Anaplastic (2) · Neuroblastoma (2) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Dermatofibrosarcoma (1)
Children's Oncology Group (12) · National Cancer Institute (NCI) (5) · Dana-Farber Cancer Institute (1) · M.D. Anderson Cancer Center (1) · Valerio Therapeutics (1) · Washington University School of Medicine (1)
United States (19) · Canada (13) · Australia (9) · Puerto Rico (8) · Netherlands (3) · New Zealand (3) · Switzerland (3) · Germany (2) · Italy (2) · Saudi Arabia (2) · Austria (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1)
Cindy Schwartz, MD (2) · Andrea Biondi (1) · Barbara L. Asselin, MD (1) · Brian A Van Tine, M.D., Ph.D. (1) · Cameron K. Tebbi, MD (1) · Elizabeth Raetz, MD (1) · Emily Greengard (1) · Henning T Mouridsen, MD, Dr. med. (1) · Howard M Katzenstein (1) · Kris Ann P Schultz (1) · Lewis B Silverman (1) · Mark Graham (1) · Mark W. Kieran, MD, PhD (1) · Maro Ohanian (1) · Michael A. Weiner, MD (1)
PMID 17185744, PMID 19064966, PMID 19584400, PMID 22689804, PMID 22911615, PMID 23393050, PMID 23664013, PMID 30975630, PMID 32154021, PMID 33095287, PMID 33843815, PMID 34028986, PMID 34652968, PMID 34874751, PMID 37073741, PMID 38107263, PMID 38947228, PMID 41920422, PMID 42497367
U10CA180886 (7), U10CA098543 (3), U01CA097452 (2), 2017 (1), P30CA006516 (1), P30CA013330 (1), P30CA016672 (1), U10CA030969 (1), U10CA031946 (1), U10CA180830 (1), UM1CA097452 (1)